Status:
COMPLETED
Study of Allogenic Adipose-derived Stem Cells in Crohn's Fistula
Lead Sponsor:
Anterogen Co., Ltd.
Conditions:
Crohn
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
Adipose-derived stem cells have properties of differentiation to various types of cells, immunomodulatory effects. adipose-derived stem cells (ASCs) show also low immunogenicity. Anterogen has develo...
Eligibility Criteria
Inclusion
- Diagnosed with Crohn's disease
- Crohn's fistula which has been lasted at least for 3 months
- Negative for beta-HCG pregnancy test
Exclusion
- Medical history with Variant Creutzfeldt Jacobs Disease
- Allergic to anesthetics or bovine protein or fibrin glue
- autoimmune disease other than Crohn's disease
- Infectious disease
- Sepsis or active tuberculosis
- pregnant or breast feeding woman
- Inflammatory Bowel disease other than Crohn's disease
- active crohn's disease with CDAI score \> 200
- malignant tumor
- fistula's diameter \> 2 cm
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 8 2012
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01440699
Start Date
September 1 2011
End Date
November 8 2012
Last Update
August 25 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Keonghee Medical Center
Seoul, South Korea
2
Seoul National University Hospital
Seoul, South Korea
3
Yeonsei Medical Center
Seoul, South Korea